EUVIMEDEUVIMED entdecken
Crossref

2025 Novel Drug Approvals

Katherine Ghattas, Amanda Rawa

Transformative Medicine · 30.03.2026 · 5 (1) · 17

DOI: 10.54299/tmed/cram4550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transformative Medicine, online erschienen am 30.03.2026. Verfasst von Katherine Ghattas und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The year 2025 marked another strong chapter in pharmaceutical innovation, with multiple novel therapies gaining approval from the U.S. Food and Drug Administration (FDA). These approvals reflect continued progress in addressing unmet medical needs across a wide range of disease states. This article reviews the FDA’s 2025 novel drug approvals, spotlighting a few therapeutic advancements and emerging trends. A comprehensive table of all approved agents is provided, along with a focused discussion of four particularly impactful therapies: donidalorsen (Dawnzera), taletrectinib (Ibtrozi), delgocitinib (Anzupgo), gepotidacin (Blujepa), etripamil (Cardamyst). Each of these agents represents a step forward in its respective field and shows the evolving landscape of modern therapeutics.

Zitieren

APA

Ghattas, K., & Rawa, A. (2026). 2025 Novel Drug Approvals. Transformative Medicine, 5(1), 17. https://doi.org/10.54299/tmed/cram4550

Vancouver

Ghattas K, Rawa A. 2025 Novel Drug Approvals. Transformative Medicine. 2026;5(1):17. doi:10.54299/tmed/cram4550

BibTeX
@article{Ghattas2026,
  author = {Ghattas, Katherine and Rawa, Amanda},
  title = {2025 Novel Drug Approvals},
  journal = {Transformative Medicine},
  year = {2026},
  volume = {5},
  number = {1},
  pages = {17},
  doi = {10.54299/tmed/cram4550}
}
Kostenlos starten →